Matinas BioPharma Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Going Concern and Plan of Operation (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Going Concern And Plan Of Operation [Line Items]
Deficit accumulated during development stage	$ (14,051,764)	$ (3,830,719)
Net loss	$ (10,221,045)us-gaap_NetIncomeLoss	$ (3,713,127)us-gaap_NetIncomeLoss

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.